Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Rheumatoid Arthritis

NCT02557295 is registered in ClinicalTrials.gov with Celltrion as lead sponsor.

NCT NCT02557295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02557295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Rheumatoid Arthritis
Lead sponsor
Celltrion
Phase
Observational
Overall status
Terminated
Start date
December 17, 2013
Completion date
March 2, 2020
Enrollment
248 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis